From Serendipity to Rational Identification of the 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one Core as a New Chemotype of AKT1 Inhibitors for Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14112295
Abstract: Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy whose prognosis is globally poor. In more than 60% of AML patients, the PI3K/AKTs/mTOR signaling pathway is aberrantly activated because of oncogenic driver alterations and further… read more here.
Keywords: myeloid leukemia; tetrahydrobenzo thieno; acute myeloid; rational identification ... See more keywords